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Introduction
Multifocal motor neuropathy (MMN) is a chronic inflammatory 
multifocal neuropathy presenting with asymmetrical distal muscle 
weakness without sensory disturbances [1]. Evidence based treatment 
of MMN is limited to immunoglobulin given intravenously or 
subcutaneously [2,3].
In patients with inflammatory polyneuropathy, physical 
exercise training has been shown to improve muscle strength and 
aerobic capacity [4-6]. These studies included primarily patients 
recovering from Guillain-Barré syndrome and therefore there is a 
lack of information about exercise in chronic forms of inflammatory 
neuropathy. In a recent study, we demonstrated that muscle strength 
and aerobic capacity increased following 12 weeks of resistance and 
aerobic exercise in patients with chronic inflammatory demyelinating 
polyneuropathy (CIDP) [7]. 




Patients diagnosed with MMN, receiving maintenance treatment 
with subcutaneous immunoglobulin (SCIG), were eligible for inclusion 
in the study. Inclusion criteria were stable clinical condition and 
Abstract
Introduction: Regular physical exercise leads to improved muscle strength and aerobic capacity in chronic inflammatory demyelinating polyneuropathy, but the effect 
in multifocal motor neuropathy (MMN) is unknown.
Methods: Of the 15 invited MMN patients, four patients performed 12 weeks of resistance exercise with unilateral training of wrist and elbow and 12 weeks of 
aerobic exercise on an ergometer bike. Exercise periods were preceded by a run-in period without scheduled exercise. Primary outcomes were changes in combined 
isokinetic strength (cIKS) and aerobic capacity (VO2-max). 
Results: Resistance exercise was well tolerated. cIKS improved at wrist by 86 %, 18 % and 16 % in three patients and at elbow by and 30 % and 16 % in two 
participants, while one patient was unchanged. VO2-max was increased in two participants by 13 and 15 %, while two participants deteriorated by 9 %.
Discussion: Resistance and aerobic exercise was feasible in MMN patients. The effects varied individually from slight decrease to considerable improvements, which 
supports further investigations of exercise in MMN. 
treatment with SCIG in the preceding three months, preserved gait 
function and age > 18 years. Exclusion criteria were known liver or 
kidney disease, other immunomodulatory treatment, regular physical 
exercise > 1 hour per week or > 4 km bicycling per day.
Participants were recruited from the outpatient clinic at the 
neurological departments at Aarhus University Hospital and 
Rigshospitalet, Copenhagen. 
The study was registered at ClinicalTrials.gov (NCT02121678) and 
was approved by the local Ethics Committee in the Central Region of 
Denmark.
Study design
At enrollment, all participants were allocated to start with either 
aerobic or resistance exercise for 12 weeks, each followed by the other 
training regimen. All participants had a run-in period of 12 weeks 
without any scheduled exercise. 
For aerobic training, participants exercised on an ergometer bike 
at home for 20-30 minutes, three times weekly. Based on maximal and 
resting heart rate from the initial VO2-max test at enrollment, the target 
heart rate of 70 % of heart rate reserve was calculated. During each 
exercise session, the participants wore a pulse belt (Polar FT7, Polar 
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Electro Oy, Finland) that recorded the average heart rate. Adherence 
to training was monitored at telephone interviews every second week, 
combined with recordings from the heart rate monitors and diary 
recordings.
Aerobic capacity was determined by measuring the maximal 
oxygen consumption rate (VO2-max) as described elsewhere and 
compared to a normal material [8,9]. 
During the resistance training period, the participants exercised 
unilaterally with dumbbells with the untrained side serving as control. 
In all participants, resistance exercises involved wrist flexors/extensors 
and elbow flexors/extensors of the most involved side. The load for 
resistance exercise was based on determination of 12-repetition-max 
(12-RM). Supervised by one of the authors (LKM), each participant 
used dumbbell to determine 12-RM. The training program used has 
been described elsewhere [7]. The weakest side was chosen for training. 
In case both sides were affected, the non-dominant side was chosed.
Combined isokinetic muscle strength (cIKS) was evaluated by 
dynamometry (BIODEX System 3, Biodex Medical Systems Inc., 
Shirley, NY, USA) as described elsewhere. Shortly, muscle strength of 
elbow and wrist flexion/extension are measured while the patient uses 
his/her maximal performance. The peak torque of eight repetitions 
were used. The sum score of wrist flexion/extension and elbow flexion/
extension were calculated and compared to a normal material [10].
Statistics
For the aerobic and resistance training, the primary outcomes were 
changes in maximal oxygen consumption (VO2-max) and cIKS at wrist 
and elbow, respectively. 
Due to the low number of participants statistical analyses were not 
performed. Consequently, all data presented in the text are medians 
(min to max). 
Results
Fifteen patients with MMN were invited to participate. Two of 
them fulfilled an exclusion criterion, nine declined to participate, 
leaving four patients who could be included. The main reason for 
this was that many patients found participation in the study time 
consuming. The median duration of MMN was 16 years prior to 
inclusion (6 to 32), and they had been treated with SCIG for 6.8 years 
(3 to 10) with a mean dose of 25.6 g/week (18 to 30) and unchanged 
for more than 12 months for all participants.
From heart rate monitors and diaries, we found that the participants 
on average exercised 2.5 times per week. The median heart rate during 
aerobic exercise was 140 beats per minute (132 to 150), which was 101 
% (98 to 108) of the target heart rate. The 1-repetition max increased 
by 70 % (32 to 102).
At enrollment all patients had a lower muscle strength of wrist and 
elbow (flexion and extension) and aerobic capacity when compared to a 
normal material with respect to gender, age and body weight (Table 1). 
During the run-in period, cIKS was overall changed by 2.8 % (-4.8 
to 6.7) on the side chosen for future training and -1.5 % (-8.9 to 4.0) on 
the control side. In the same period, aerobic capacity changed by 3.4 % 
(-31 to 5.3). 
At the wrist, cIKS increased in three patients by 86.0 % (#1), 19% 
(#3) and 16 % (#4), whereas one patient decreased by 8% (#2) (Figure 
1A). At the elbow, cIKS also increased in three patients by 30% (#1), 
16% (#3) and 7% (#4) and decreased in one patient by 8% (#2) (Figure 
1B). On the control side, muscle strength was increased by 13.6 % (#1) 
and 18.3 % (#3) or unchanged (-6.0 % (#2) and -5.3 % (#4)). This could 
be due to a low muscle strength before initiation of exercise in this 
patient compared to the other three (Table 1). In contrast, the other 
three patients did not experience any significant changes. 
During aerobic training, we found that aerobic capacity on average 
was unaltered. Thus, two patients experienced an increase in aerobic 
capacity of 13 % (#4) and 15 % (#3), whereas the two other patients had 
a decrease of 9 % (#1 and #2) (Figure 1C).
One patient (#2) complained of lower back pain during aerobic 
training and withdrew consent after 8 weeks of training although the 
patient completed the resistance training. None of the participants had 
any side effects to resistance training.
Discussion
In this small study of resistance and aerobic training in MMN, we 
did not find a consistent improvement of muscle strength or aerobic 
capacity after training.
The effect of training has not been evaluated earlier in MMN. 
In a recent study from our group, using the same training protocols, 
we demonstrated a positive effect of resistance and aerobic training 
in patients with CIDP. Among these patients, an increase of muscle 
strength of 14 % following unilateral resistance training and an increase 
of aerobic capacity of 11 % following aerobic training was statistically 
significant [7]. 
Patient #1 #2 #3 #4
Sex F M F F
Age 60 45 67 63
Duration of MMN (years) 20 6 32 6
Dose of SCIG
(g/week) 30 18 28 26.4
Isokinetic muscle strength at enrollment 
(pct of norm)
Wrist flexion trained/untrained 29 / 31 68 / 85 78 / 71 58 / 77
Wrist extension trained/untrained 38 / 48 88 / 76 69 / 120 36 / 112
Elbow flexion trained/untrained 48 / 57 111 / 95 40 / 26 63 / 94
Elbow extension trained/untrained 32 / 47 57 / 100 56 / 58 13 / 79
Aerobic capacity at enrollment 
(pct of norm)
VO2-max             58 82 44 69
Table 1. Baseline characteristics and changes in isokinetic muscle strength (cIKS) and aerobic capacity (VO2-max) for each of the four MMN patients included
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Figure 1. Individual changes in isokinetic muscle strength (cIKS) at wrist (A) and elbow 
(B) and the maximal oxygen consumption velocity (VO2-max) (C) relative to baseline level 
during the training period (from week 0 to 12)
The low number of participants was due to only few patients 
accepting participation and the low prevalence of MMN, 0.6 to 2.0 per 
100,000 (1) giving only up to 100 patients in Denmark. Some patients 
remain undiagnosed and others are treated with IVIG instead of SCIG. 
As IVIG is related to fluctuations in muscle strength between the 
infusions, only SCIG treated patients were eligible for inclusion in this 
study. The fraction of patients with MMN accepting and qualifying to 
participate (4 out of 15 (28 %)) was similar to our study of exercise in 
CIDP [7].
Overall, the changes in muscle strength and aerobic capacity were 
inconsistent, but it is interesting that three of the four patients had an 
increase in muscle strength and only one had no effect. An increase of 
more than 10% on cIKS has previously been considered being clinical 
significant [11]. For the aerobic capacity two patients had increases 
of 13 and 15 %, whereas the other two had small decreases. As the 
weekly exercise sessions were unsupervised, we cannot be sure that the 
patients actually performed the exercise according to protocol. The use 
of diaries and regular contact by telephone or e-mail was the best way 
for us to encourage the participants to train sufficiently, and to increase 
load for resistance exercise. The self reported adherence to training was 
comparable to what we have previously shown for CIDP patients [7]. The 
MMN patients even increased their 1-RM more than CIDP patients, but 
at least one patient still did not obtain an increase in isokinetic muscle 
strength. Similarly, variable effects were shown for aerobic capacity 
after aerobic training. One explanation for the inconsistent findings is 
the low number of participants, but other possible explanations could 
be the long duration of disease in the MMN patients (13 years, range: 
6 to 32), and the fact that 75 % of the participants were older than 60 
years. On the other hand, patient #1 and #3 have had MMN for 20 and 
32 years and had both remarkable increase in muscle strength at both 
wrist (86 % vs 18 %) and elbow (29 % vs 17 %). Patient #4 only had 
remarkable increase at wrist, and patient #2 did not have increase at 
any time during the exercise period. He was also the only patient with a 
general higher muscle strength compared to the normal material. These 
findings indicate that it is possible to gain muscle strength at wrist and 
elbow despite most MMN patients are severely affected in these muscle 
groups.
Patient #2 had an unexplained decrease in aerobic capacity 
during the run-in period of nearly 30 % but did regain this prior 
to the start of the aerobic exercise period. Moreover, there was a 
decrease of muscle strength during the resistance exercise period. 
When evaluating this patient’s training diary, it is clear that training 
was not performed three times weekly and that the increase in loads 
during the resistance period was insufficient. Finally, the patient 
dropped out of the study after eight weeks of aerobic exercise due 
to lower back pain. 
Based on the reports of side effects from the patients, we find 
that resistance exercise in MMN is safe and feasible. As one patient 
developed back pain due to the aerobic training, and that the average 
aerobic capacity was unchanged it is unclear whether this is beneficial 
for MMN patients.
In conclusion, our findings show that resistance training is safe 
and may improve muscle strength at severely affected muscle groups. 
Aerobic capacity in patients with MMN is increased in some patients, 
but not in all and one patient developed lower back pain during aerobic 
exercise. These findings suggest that further and larger studies of 
exercise in MMN are needed.
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